Trial · NCT02421172
Results by group34
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 34
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinical Responder Rate at Period 1: Week 16 | Period 1: CJM112 High Dose | 10 | participants | ||
| Clinical Responder Rate at Period 1: Week 16 | Period 1: Placebo | 4 | participants | ||
| Clinical Responder Rate Period 1 at Week 2, 4, 8 and 12 | Period 1: CJM112 High Dose | Week 2 | 4 | count of participants | |
| Clinical Responder Rate Period 1 at Week 2, 4, 8 and 12 | Period 1: Placebo | Week 2 | 3 | count of participants | |
| Clinical Responder Rate Period 1 at Week 2, 4, 8 and 12 | Period 1: CJM112 High Dose | Week 4 | 6 | count of participants | |
| Clinical Responder Rate Period 1 at Week 2, 4, 8 and 12 | Period 1: Placebo | Week 4 | 3 | count of participants | |
| Clinical Responder Rate Period 1 at Week 2, 4, 8 and 12 | Period 1: CJM112 High Dose | Week 8 | 5 | count of participants | |
| Clinical Responder Rate Period 1 at Week 2, 4, 8 and 12 | Period 1: Placebo | Week 8 | 6 | count of participants | |
| Clinical Responder Rate Period 1 at Week 2, 4, 8 and 12 | Period 1: CJM112 High Dose | Week 12 | 7 | count of participants | |
| Clinical Responder Rate Period 1 at Week 2, 4, 8 and 12 | Period 1: Placebo | Week 12 | 4 | count of participants | |
| Pharmacokinetics (PK): Ctrough for CJM112 Period 1 and Period 2 | Period 1: CJM112 High Dose | 21.4 | Standard Deviation 11.6 | ug/mL | |
| Pharmacokinetics (PK): Ctrough for CJM112 Period 1 and Period 2 | Extension Period 2: Placebo/CJM112 Low Dose | 3.1 | Standard Deviation 2.6 | ug/mL | |
| Pharmacokinetics (PK): Ctrough for CJM112 Period 1 and Period 2 | Extension Period 2: Placebo/CJM112 High Dose | 24.4 | Standard Deviation 19.0 | ug/mL | |
| Pharmacokinetic Profile: T1/2 The Terminal Elimination Half-life for Period 1 & Period 2/End of Study | Period 1: CJM112 High Dose | 16.09 | Standard Deviation 3.500 | days | |
| Pharmacokinetic Profile: T1/2 The Terminal Elimination Half-life for Period 1 & Period 2/End of Study | Extension Period 2: Placebo/CJM112 Low Dose | 22.81 | Standard Deviation 0 | days | |
| Pharmacokinetic Profile: T1/2 The Terminal Elimination Half-life for Period 1 & Period 2/End of Study | Extension Period 2: Placebo/CJM112 High Dose | 19.85 | Standard Deviation 3.807 | days | |
| Immunogenicity - Incidence of ADA-positive and ADA-negative in Participants With or Without Pre-existing Antibodies in Period 1 and Period 2/End of Study | Period 1: CJM112 High Dose | Pre-existing Antibodies ADA negative | 2 | participants | |
| Immunogenicity - Incidence of ADA-positive and ADA-negative in Participants With or Without Pre-existing Antibodies in Period 1 and Period 2/End of Study | Extension Period 2: Placebo/CJM112 Low Dose | Pre-existing Antibodies ADA negative | 1 | participants | |
| Immunogenicity - Incidence of ADA-positive and ADA-negative in Participants With or Without Pre-existing Antibodies in Period 1 and Period 2/End of Study | Extension Period 2: Placebo/CJM112 High Dose | Pre-existing Antibodies ADA negative | 7 | participants | |
| Immunogenicity - Incidence of ADA-positive and ADA-negative in Participants With or Without Pre-existing Antibodies in Period 1 and Period 2/End of Study | Period 1: CJM112 High Dose | Pre-existing Antibodies ADA positive | 1 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02421172/results